Vor Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
04/08/2025 23:40
Vor Biopharma Inc VOR.OQ VOR.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for Vor Biopharma Inc is for a loss of 44 cents per share. The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts had risen by about 8.9% in the last three months. Wall Street's median 12-month price target for Vor Biopharma Inc is $0.70, about 201.4% below its last closing price of $2.11 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.22 | -0.23 | -0.26 | Missed | -13.8 |
| Dec. 31 2025 | -0.22 | -0.29 | -0.44 | Missed | -54 |
| Sep. 30 2024 | -0.41 | -0.40 | -0.40 | Met | 0.5 |
| Jun. 30 2024 | -0.42 | -0.42 | -0.41 | Beat | 1.9 |
| Mar. 31 2024 | -0.38 | -0.38 | -0.45 | Missed | -18.9 |
| Dec. 31 2023 | -0.52 | -0.50 | -0.39 | Beat | 22.5 |
| Sep. 30 2023 | -0.47 | -0.47 | -0.49 | Missed | -4.6 |
| Jun. 30 2023 | -0.44 | -0.43 | -0.45 | Missed | -4.1 |
Recent news on Vor Biopharma
See all newsBrief: Telitacicept Demonstrates Durable Preservation Of Kidney Function Through Two Years In Phase 3 Teligan Trial In Iga Nephropathy
Vor Bio says its experimental drug slowed loss of kidney function in late-stage study
U.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning